{"id":"W4387451565","doi":"10.1038/s41591-023-02598-9","title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Kingston Health Sciences Centre; University Health Network; Hamilton Health Sciences; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Canada; EMD Serono; Genentech; National Institutes of Health; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Johns Hopkins University; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Cancer Research Institute","keywords":"Medicine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Pembrolizumab; Oncology; Lung cancer; Confidence interval; Progression-free survival; Randomized controlled trial; Immunotherapy; Phases of clinical research; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003338731,0.001499409,0.001251856,0.0002781725,0.0002515149,0.0009615733,0.0006818505,0.001294864,0.002338893],"category_scores_gemma":[0.001804874,0.000288887,0.0009659248,0.0002016899,0.0006558622,0.0007142822,0.0003696314,0.002509782,0.0004388539],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005965948,"about_ca_system_score_gemma":0.0008988262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003533956,"about_ca_topic_score_gemma":0.0007396709,"domain_scores_codex":[0.9990311,0.0005591177,0.00004673521,0.0001371726,0.000105294,0.0001207037],"domain_scores_gemma":[0.9993187,0.0001965017,0.0001436086,0.00007642061,0.0000595338,0.0002052648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7560593,0.04170197,0.007873037,0.001055923,0.00139162,0.00025828,0.0003117598,0.003616065,0.05334611,0.0006839756,0.004413597,0.1292884],"study_design_scores_gemma":[0.6201024,0.3485833,0.01434166,0.00008885521,0.0004901576,0.0003211183,0.00004087813,0.00288169,0.007808658,0.0005562398,0.004739206,0.00004571048],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907079,0.001661707,0.0008868615,0.0007844444,0.0001057146,0.002311169,0.001315627,0.0001125835,0.002114063],"genre_scores_gemma":[0.9818479,0.001097612,0.00349152,0.001545354,0.0003698302,0.004636631,0.003197291,0.00004703711,0.003766741],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003338731,"threshold_uncertainty_score":0.0176571,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00815115059855832,"score_gpt":0.3022338058159968,"score_spread":0.2940826552174385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}